Benzinga | Nov 4, 2021 10:31AM EDT

Karyopharm Announces New Interim Phase 2 Selinexor Data In Myelofibrosis Selected For Oral Presentation At American Society Of Hematology 2021 Annual Meeting And Exposition

Karyopharm Therapeutics Inc. (NASDAQ:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that an abstract detailing new data from a Phase 2 study evaluating selinexor, a first-in-class, oral Selective Inhibitor of Nuclear Export (SINE) compound, in patients with myelofibrosis (MF) previously treated with JAK inhibition has been selected for an oral presentation at the upcoming American Society of Hematology (ASH) 2021 Annual Meeting and Exposition in Atlanta, GA on December 11-14, 2021.

"JAK inhibition is the current standard of care for patients with myelofibrosis; however, patients whose disease fails treatment with ruxolitinib have a poor prognosis, with an expected survival of approximately 14 months, and there are no approved treatment options other than JAK inhibitors," said Srinivas Tantravahi, MBBS, MRCP, University of Utah Hospital and principal investigator of the Phase 2 study. "Interim results from this Phase 2 study demonstrated that once weekly single agent oral selinexor resulted in compelling spleen volume reduction rates in myelofibrosis patients who received at least 24 weeks of treatment, with 33% of those patients achieving a response, defined as ?35% SVR. In addition to spleen responses, there was improvement in anemia status and symptom scores in these patients. The responses were durable with the first patient on treatment for more than two years. The sustained responses and well-tolerated safety profile highlight selinexor's potential in patients with myelofibrosis who have either progressed following ruxolitinib or cannot tolerate JAK inhibition. We look forward to sharing these exciting results with the broader medical and scientific community at ASH this year."

"Once weekly, low-dose selinexor is an oral agent with a unique mechanism of action that has demonstrated strong single-agent activity in myelofibrosis patients with disease refractory to ruxolitinib," said Jatin Shah, MD, Chief Medical Officer of Karyopharm. "Importantly, there are no other classes of drug approved other than JAK inhibitors and a new class of effective drugs is a critical need for patients. Based on these encouraging data, we look forward to dosing the first patient in a new, company-sponsored Phase 2 study evaluating single-agent selinexor versus physician's choice in patients with previously treated myelofibrosis during the fourth quarter of 2021."